A novel recurrent copy number loss region on 6q23.3 in MDS-related myeloid malignancy patients with stable survival conditions

References

• Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322–2333.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–4336.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312–1320.
   PubMed Web of Science ®Google Scholar
• Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–4395.
   PubMed Web of Science ®Google Scholar
• Cherry AM, Brockman SR, Paternoster SF, et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res. 2003;27:1085–1090.
   PubMed Web of Science ®Google Scholar
• Jiang H, Xue Y, Wang Q, et al. The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure. Leuk Res. 2012;36:448–452.
   PubMed Web of Science ®Google Scholar
• Dunbar AJ, Gondek LP, O'Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68:10349–10357.
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Valle VD, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289–2301.
   PubMed Web of Science ®Google Scholar
• Puda A, Milosevic JD, Berg T, et al. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol. 2012;87:245–250.
   PubMed Web of Science ®Google Scholar
• Tiu RV, Gondek LP, O'Keefe CL, et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol. 2009;27:5219–5226.
   PubMed Web of Science ®Google Scholar
• Tiu RV, Gondek LP, O'Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011;117:4552–4560.
   PubMed Web of Science ®Google Scholar
• Shaffer LG, Slovak ML, Campbell LJ. An International System for Human Cytogenetic Nomenclature (2009). International Standing Committee on Human Cytogenetic Nomenclature; 2009.
   Google Scholar
• Chi K, Li Y, Ding Q, et al. High resolution SNP array (SNP-A) reveals cryptic indicating information about MDS-related myeloid malignancies. Leuk Lymphoma. 2015;1–12.
   Web of Science ®Google Scholar
• Shen Y, Zhu Y-M, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118:5593–5603.
   PubMed Web of Science ®Google Scholar
• Chen CY, Lin LI, Tang JL, et al. RUNX1 gene mutation in primary myelodysplastic syndrome—the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol. 2007;139:405–414.
   PubMed Web of Science ®Google Scholar
• Mullally A, Ebert BL. NF1 inactivation revs up Ras in adult acute myelogenous leukemia. Clin Cancer Res. 2010;16:4074–4076.
   PubMed Web of Science ®Google Scholar
• Austin GE, Chan WC, Zhao W, et al. Myeloperoxidase gene expression in normal granulopoiesis and acute leukemias. Leuk Lymphoma. 1994;15:209–226.
   PubMed Web of Science ®Google Scholar
• Nauseef WM, Olsson I, Arnljots K. Biosynthesis and processing of myeloperoxidase—a marker for myeloid cell differentiation. Eur J Haematol. 1988;40:97–110.
   PubMed Web of Science ®Google Scholar
• Heinrichs S, Kulkarni RV, Bueso-Ramos CE, et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia. 2009;23:1605–1613.
   PubMed Web of Science ®Google Scholar
• Gondek LP, Tiu R, O'Keefe CL, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008;111:1534–1542.
   PubMed Web of Science ®Google Scholar
• Cargo CA, Rowbotham N, Evans PA, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood. 2015;126:2362–2365.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–2506.
   PubMed Web of Science ®Google Scholar
• Xu F, Wu LY, Chang CK, et al. Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes. Nat Commun. 2015;6:8806.
   PubMed Web of Science ®Google Scholar
• Schoch C, Haferlach T, Bursch S, et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosom Cancer. 2002;35:20–29.
   PubMed Web of Science ®Google Scholar
• Mohamedali A, Gäken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood. 2007;110:3365–3373.
   PubMed Web of Science ®Google Scholar
• Dicker F, Haferlach C, Sundermann J, et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia. 2010;24:1528–1532.
   PubMed Web of Science ®Google Scholar
• Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23:4284–4296.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Kanegane H, Osato M, et al. Functional analysis of RUNX2 mutations in cleidocranial dysplasia: novel insights into genotype-phenotype correlations. Blood Cells Mol Dis. 2003;30:184–193.
   PubMed Web of Science ®Google Scholar
• Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166–175.
   PubMed Web of Science ®Google Scholar
• Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364–1372.
   PubMed Web of Science ®Google Scholar
• Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood. 2004;104:1474–1481.
   PubMed Web of Science ®Google Scholar
• Klempnauer KH, Gonda TJ, Bishop JM. Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: the architecture of a transduced oncogene. Cell. 1982;31:453–463.
   PubMed Web of Science ®Google Scholar
• Leprince D, Gegonne A, Coll J, et al. A putative second cell-derived oncogene of the avian leukaemia retrovirus E26. Nature. 1983;306:395–397.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ness SA. Myb proteins: angels and demons in normal and transformed cells. Front Biosci (Landmark Ed). 2011;16:1109–1131.
   PubMed Web of Science ®Google Scholar
• Emambokus N, Vegiopoulos A, Harman B, et al. Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. EMBO J. 2003;22:4478–4488.
   PubMed Web of Science ®Google Scholar
• Garcia P, Clarke M, Vegiopoulos A, et al. Reduced c-Myb activity compromises HSCs and leads to a myeloproliferation with a novel stem cell basis. EMBO J. 2009;28:1492–1504.
   PubMed Web of Science ®Google Scholar
• Tapper W, Jones AV, Kralovics R, et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015;6:6691.
   PubMed Web of Science ®Google Scholar
• Sarvaiya PJ, Schwartz JR, Hernandez CP, et al. Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis. Am J Hematol. 2012;87:969–976.
   PubMed Web of Science ®Google Scholar
• Erdogan B, Facey C, Qualtieri J, et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol. 2011;39:915–926. e912.
   PubMed Web of Science ®Google Scholar
• Anfossi G, Gewirtz AM, Calabretta B. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl Acad Sci USA. 1989;86:3379–3383.
   PubMed Web of Science ®Google Scholar
• Calabretta B, Sims RB, Valtieri M, et al. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA. 1991;88:2351–2355.
   PubMed Web of Science ®Google Scholar
• Gilliland DG. Targeted therapies in myeloid leukemias. Ann Hematol. 2004;83 Suppl.1:S75–S76.
   PubMedGoogle Scholar
• Frohling S, Scholl C, Gilliland DG, et al. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol. 2005;23:6285–6295.
   PubMed Web of Science ®Google Scholar
• Grisolano JL, O'Neal J, Cain J, et al. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA. 2003;100:9506–9511.
   PubMed Web of Science ®Google Scholar
• Kelly LM, Kutok JL, Williams IR, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA. 2002;99:8283–8288.
   PubMed Web of Science ®Google Scholar
• Rocquain J, Carbuccia N, Trouplin V, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010;10:401.
   PubMed Web of Science ®Google Scholar